{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:16:13Z","timestamp":1794885373239,"version":"4.9.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.lanepe.2024.100853","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T17:44:23Z","timestamp":1707500663000},"page":"100853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0\u00a0mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5044-1515","authenticated-orcid":false,"given":"Dimitris","family":"Papamargaritis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werd","family":"Al-Najim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Z.M.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle H.","family":"Bodicoat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-8404","authenticated-orcid":false,"given":"John P.H.","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel W.","family":"le Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-9371","authenticated-orcid":false,"given":"Melanie J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.lanepe.2024.100853_bib1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/obr.12551","article-title":"Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation","volume":"18","author":"Bray","year":"2017","journal-title":"Obes Rev"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100853_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/2042533313512479","article-title":"Eligibility for bariatric surgery among adults in England: analysis of a national cross-sectional survey","volume":"5","author":"Ahmad","year":"2014","journal-title":"JRSM Open"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100853_bib3","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s13679-020-00416-8","article-title":"Developing integrated clinical pathways for the management of clinically severe adult obesity: a critique of NHS england policy","volume":"9","author":"Hazlehurst","year":"2020","journal-title":"Curr Obes Rep"},{"issue":"68","key":"10.1016\/j.lanepe.2024.100853_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22680","article-title":"Bariatric surgery, lifestyle interventions and orlistat for severe obesity: the REBALANCE mixed-methods systematic review and economic evaluation","volume":"22","author":"Avenell","year":"2018","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100853_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/oby.20662","article-title":"Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study","volume":"22","year":"2014","journal-title":"Obesity"},{"issue":"11","key":"10.1016\/j.lanepe.2024.100853_bib7","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/s41366-021-00915-1","article-title":"Extended follow-up of a short total diet replacement programme: results of the Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET) randomised controlled trial at 3 years","volume":"45","author":"Astbury","year":"2021","journal-title":"Int J Obes"},{"issue":"5","key":"10.1016\/j.lanepe.2024.100853_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial","volume":"7","author":"Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.lanepe.2024.100853_bib9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ajcn\/74.5.579","article-title":"Long-term weight-loss maintenance: a meta-analysis of US studies","volume":"74","author":"Anderson","year":"2001","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100853_bib10","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/oby.23371","article-title":"Benefits of weight loss of 10% or more in patients with overweight or obesity: a review","volume":"30","author":"Tahrani","year":"2022","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100853_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.lanepe.2024.100853_bib12","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100853_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/oby.22359","article-title":"Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial","volume":"27","author":"Wadden","year":"2019","journal-title":"Obesity"},{"issue":"7","key":"10.1016\/j.lanepe.2024.100853_bib14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"10077","key":"10.1016\/j.lanepe.2024.100853_bib15","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lanepe.2024.100853_bib16","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/oby.21629","article-title":"Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers","volume":"24","author":"Fujioka","year":"2016","journal-title":"Obesity"},{"key":"10.1016\/j.lanepe.2024.100853_bib17","series-title":"Technology appraisal guidance [TA664]: liraglutide for managing overweight and obesity","year":"2020"},{"issue":"8","key":"10.1016\/j.lanepe.2024.100853_bib18","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes"},{"issue":"8","key":"10.1016\/j.lanepe.2024.100853_bib19","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2337\/dc15-1081","article-title":"Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors' expert forum","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.lanepe.2024.100853_bib20","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100853_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/cob.12146","article-title":"Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management","volume":"6","author":"Kolotkin","year":"2016","journal-title":"Clin Obes"},{"issue":"2","key":"10.1016\/j.lanepe.2024.100853_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034137","article-title":"Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial","volume":"10","author":"Papamargaritis","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.lanepe.2024.100853_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity"},{"issue":"8","key":"10.1016\/j.lanepe.2024.100853_bib24","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.lanepe.2024.100853_bib25","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Gregg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.lanepe.2024.100853_bib26","article-title":"New therapies for obesity","author":"Papamargaritis","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.lanepe.2024.100853_bib27","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s11136-015-1153-x","article-title":"Health-related quality of life in two randomized controlled trials of phentermine\/topiramate for obesity: what mediates improvement?","volume":"25","author":"Kolotkin","year":"2016","journal-title":"Qual Life Res"},{"issue":"11","key":"10.1016\/j.lanepe.2024.100853_bib28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.lanepe.2024.100853_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266677622400019X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266677622400019X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T13:27:38Z","timestamp":1729085258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266677622400019X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":28,"alternative-id":["S266677622400019X"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100853","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0\u00a0mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100853","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100853"}}